(S)-2-(4’-Bromo-[1,1’-Biphenyl]-4-Ylsulfonamido)-3-Methylbutanoic Acid (S)-2-(4’-溴-[1,1’-联苯]-4-基磺酰胺基)-3-甲基丁酸

CAS 199850-67-4 MFCD09038565

化学结构图

199850-67-4
SMILES: CC(C)[C@H](NS(=O)(=O)C1=CC=C(C=C1)C1=CC=C(Br)C=C1)C(O)=O

化学属性

Mol. FormulaC17H18BrNO4S
Mol. Weight412.302

别名和识别编码

Chemical Name(S)-2-(4’-Bromo-[1,1’-Biphenyl]-4-Ylsulfonamido)-3-Methylbutanoic Acid
Chemical Name Translation(S)-2-(4’-溴-[1,1’-联苯]-4-基磺酰胺基)-3-甲基丁酸
信息真实价格透明    资金保障    专业采购外包团队在线服务   
信息真实价格透明    资金保障    专业采购外包团队在线服务   
品牌质保精细包装    现货库存    一流品牌服务   

相关文献及参考

  • [2]. Kaludercic N, et, al. Inhibiting metalloproteases with PD 166793 in heart failure: impact on cardiac remodeling and beyond. Cardiovasc Ther. Spring 2008;26(1):24-37.
  • [3]. Chancey AL, et, al. Effects of matrix metalloproteinase inhibition on ventricular remodeling due to volume overload. Circulation. 2002 Apr 23;105(16):1983-8.
  • [1]. O'Brien PM, et, al. Structure-activity relationships and pharmacokinetic analysis for a series of potent, systemically available biphenylsulfonamide matrix metalloproteinase inhibitors. J Med Chem. 2000 Jan 27;43(2):156-66.
  • [1]. O'Brien PM, et, al. Structure-activity relationships and pharmacokinetic analysis for a series of potent, systemically available biphenylsulfonamide matrix metalloproteinase inhibitors. J Med Chem. 2000 Jan 27;43(2):156-66.
  • [2]. Kaludercic N, et, al. Inhibiting metalloproteases with PD 166793 in heart failure: impact on cardiac remodeling and beyond. Cardiovasc Ther. Spring 2008;26(1):2

系列性分类

  1. Medical Research Areas
  2. Metabolism
  3. MMP  (基质金属蛋白酶)

相关产品推荐